Last edition
News about "Head and Neck Squamous Cell Carcinoma (HNSCC)"
Johnson & Johnson's RYBREVANT FASPRO Gets US FDA Priority Review for Advanced Head and Neck Cancer
Johnson & Johnson's RYBREVANT FASPRO has received US Food and Drug Administration (FDA) Priority Review (PR) as a potential first-in-class subcutaneous treatment for advanced head and neck cancer.
Head And Neck Squamous Cell Carcinoma (HNSCC) | 01/08/2026 | By News Bureau
Radiopharm Theranostics Begins Enrollment for Third Cohort in Phase 1 Trial of 177Lu-RAD204
Radiopharm Theranostics has opened enrollment for the third cohort of its Phase 1 dose-escalation trial of 177Lu-RAD204, after the Data Safety Monitoring Committee cleared escalation to a 90 mCi dose. Early results from the first two cohorts show tumour uptake and a favourable safety profile.
Head And Neck Squamous Cell Carcinoma (HNSCC) | 15/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy